AVTX CIK: 1534120

Avalo Therapeutics, Inc.

  • United States
  • Healthcare
  • Biotech
Metrics score locked — part of Premium
FY21
FY22
FY23
FY24
FY25
FY21 – FY25
(positive)
Change from FY21 to FY25
millions USD
FY21:
−70.9
FY22:
−26.8
FY23:
−30.7
FY24:
−49.1
FY25:
−51.5
Change from FY21 to FY25
millions USD
FY21:
−0.11
FY22:
−0.10
FY23:
−0.13
FY24:
0.36
FY25:
−81.7
Change from FY21 to FY25
millions USD
FY21:
107
FY22:
−14.7
FY23:
25.0
FY24:
176
FY25:
14.6
millions USD
FY21:
35.8
FY22:
−41.5
FY23:
−5.77
FY24:
127
FY25:
−119
(positive)
Change from FY21 to FY23
millions USD
FY21:
−71.0
FY22:
−26.8
FY23:
−30.7
FY24:
–
FY25:
–

All amounts in millions USD Data source:SEC EDGAR